Invivyd
NASDAQ: IVVD4 known investors
Invivyd develops monoclonal antibody medicines for the prevention and treatment of serious viral infectious diseases, starting with COVID-19 and other high-need indications. It uses a proprietary integrated technology platform to design antibodies that are more potent and resistant to viral evolution.
BiotechHealthtech
Investors · 4
Competitors · 3
by search overlapIQVIA36 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Bioworld28 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Seeking Alpha24 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.
Companies competing with Invivyd for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Invivyd do?
- Invivyd develops monoclonal antibody medicines for the prevention and treatment of serious viral infectious diseases, starting with COVID-19 and other high-need indications. It uses a proprietary integrated technology platform to design antibodies that are more potent and resistant to viral evolution.
- Who are Invivyd's investors?
- Invivyd's investors include Bain Capital Life Sciences, Foresite Capital, MRL Ventures Fund, Premji Invest.